Indexing
CÁC SỐ TỪ 2011-2023
Tạp chí Y Dược Học
Abstract
Background: Osteoporosis (OP) treatments such as bisphosphonates have been proven effective in increasing bone mineral density (BMD) and reducing fracture (Fx) risk. However, according to the literature, the rate of pharmacological treatment for OP remains lower than expected. Our study was conducted to determine the prevalence of osteoporosis treatment in the elderly population and identify related factors, thereby contributing epidemiological data to the management of OP in the elderly in Vietnam.
Objective: To investigate the rate of pharmacological treatment and associated factors in elderly patients with OP at University Medical Center Ho Chi Minh City (UMC HCMC).
Subjects and Methods: This was a cross-sectional study conducted on 482 elderly patients (≥ 60 years old) who underwent BMD measurement at UMC HCMC from November 2022 to May 2023. Patient data were collected including demographics, comorbidities, activities of daily living (ADL), instrumental activities of daily living (IADL), history of OP-related fractures, OP diagnosis and treatment, follow-up information from medical records, BMD results, OP counseling, and patient knowledge about OP obtained through direct interviews.
Results: 73.9% of elderly patients with osteoporosis were treated with osteoporosis medications. Factors associated with receiving treatment included: a BMD-based diagnosis of osteoporosis (OR = 4.49, p = 0.025), receiving osteoporosis counseling after BMD assessment (OR = 7.45, p < 0.001), diagnosis by a rheumatologist (OR = 53.63, p = 0.003), patient perception of the benefits of osteoporosis treatment (OR = 9.82, p = 0.021), chronic kidney disease (OR = 0.27, p = 0.030), and atrial fibrillation (AF) (OR = 0.03, p = 0.019).
Conclusion: The rate of pharmacological treatment for osteoporosis in elderly patients at UMC HCMC was relatively high, at 73.9%. Factors such as BMD results, post-assessment OP counseling, diagnosis by a rheumatologist, and patient understanding of treatment benefits increased the likelihood of receiving treatment. In contrast, atrial fibrillation was associated with a lower likelihood of being treated for OP.
| Published | 2026-03-30 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 1 (2026) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2026.1.1041 | |
| Keywords |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R. Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication. Saudi Pharm J. 2018;26(2):238-43.
Sattari M, Cauley JA, Garvan C, Johnson KC, LaMonte MJ, Li W, et al. Osteoporosis in the Women’s Health Initiative: Another Treatment Gap? Am J Med. 2017;130(8):937-48.
LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-102.
Bianchi ML, Duca P, Vai S, Guglielmi G, Viti R, Battista C, et al. Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int. 2015;26(5):1629-38.
Kanis JA, Svedbom A, Harvey N, McCloskey EV. The osteoporosis treatment gap. J Bone Miner Res. 2014;29(9):1926-8.
Morell S, Hemmeler C, Amsler F, Gross T. Adherence to osteoporosis pharmacotherapy one year after osteoporotic fracture - a Swiss trauma center secondary prevention project. Swiss Med Wkly. 2017;147:w14451.
Majumdar SR, McAlister FA, Johnson JA, Weir DL, Bellerose D, Hanley DA, et al. Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporos Int. 2014;25(9):2173-9.
Cao Thanh N, Phạm Ngọc Thuỳ Trang, Phạm Hoàng Hải. Tình hình điều trị loãng xương và các yếu tố liên quan ở người cao tuổi gãy xương đốt sống. Tạp Chí Y học Việt Nam. 2024;538.
Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34(1):195-202.
Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3-44.
Beaton DE, Dyer S, Jiang D, Sujic R, Slater M, Sale JE, et al. Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy’s fracture clinic screening program. Osteoporos Int. 2014;25(1):289-96.
Saadi H, Litaker D, Mills W, Kippes C, Richmond B, Licata A. Practice variation in the diagnosis and treatment of osteoporosis: a case for more effective physician education in primary care. J Womens Health Gend Based Med. 1999;8(6):767-71.